In a month that has already seen a large step towards marketing approval for its first therapeutic, Ryplazim™, the Corporation focussed on the biology of healing has made two further important announcements this week. On Monday, Prometic revealed that it had entered into a binding letter of intent to secure a CAD $100m line of credit from an affiliate of one of its staunchest backers, Thomvest Asset Management.
26 Oct 2017
Further strong progress on funding, and regulatory pathway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further strong progress on funding, and regulatory pathway
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
26 Oct 2017 -
Author:
Derren Nathan -
Pages:
6
In a month that has already seen a large step towards marketing approval for its first therapeutic, Ryplazim™, the Corporation focussed on the biology of healing has made two further important announcements this week. On Monday, Prometic revealed that it had entered into a binding letter of intent to secure a CAD $100m line of credit from an affiliate of one of its staunchest backers, Thomvest Asset Management.